Novo Nordisk Total Depreciation and Amortization - Cash Flow 2010-2025 | NVO
Novo Nordisk annual/quarterly total depreciation and amortization - cash flow history and growth rate from 2010 to 2025. Total depreciation and amortization - cash flow can be defined as the total amount of depreciation and amortization listed on the Cash Flows Statement
- Novo Nordisk total depreciation and amortization - cash flow for the quarter ending March 31, 2025 was $0.540B, a 27.37% increase year-over-year.
- Novo Nordisk total depreciation and amortization - cash flow for the twelve months ending March 31, 2025 was $7.058B, a 114.02% increase year-over-year.
- Novo Nordisk annual total depreciation and amortization - cash flow for 2024 was $2.771B, a 102.71% increase from 2023.
- Novo Nordisk annual total depreciation and amortization - cash flow for 2023 was $1.367B, a 31.11% increase from 2022.
- Novo Nordisk annual total depreciation and amortization - cash flow for 2022 was $1.042B, a 8.75% increase from 2021.
Novo Nordisk Annual Total Depreciation and Amortization - Cash Flow
(Millions of US $) |
| 2024 |
$2,771 |
| 2023 |
$1,367 |
| 2022 |
$1,042 |
| 2021 |
$959 |
| 2020 |
$881 |
| 2019 |
$849 |
| 2018 |
$600 |
| 2017 |
$483 |
| 2016 |
$474 |
| 2015 |
$440 |
| 2014 |
$612 |
| 2013 |
$499 |
| 2012 |
$465 |
| 2011 |
$0 |
| 2010 |
$440 |
| 2009 |
$478 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$300.754B |
$42.122B |
|
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
|
